[Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
D000328:Adult; D002064:Buserelin; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage*; D004341:Drug Evaluation; D004717:Endometrium / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077563:Norethindrone Acetate; D010060:Ovulation / Q000187:drug effects*; D010342:Patient Acceptance of Health Care; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced; D014592:Uterine Hemorrhage / Q000139:chemically induced
D003276:Contraceptives, Oral; D003280:Contraceptives, Oral, Synthetic; D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D000077563:Norethindrone Acetate; D002064:Buserelin; D009640:Norethindrone
Fortschritte in der kontrazeptiven Anwendung des LH-RH-Agonisten Buserelin: diskontinuierliche Medikation mit gestageninduzierter Abbruchblutung.